40.58
+0.01(+0.02%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
315
First IPO Date
May 25, 2018
| Name | Title | Pay | Year Born |
| Mr. Sanj K. Patel | Chief Executive Officer & Chairman of the Board | 1.64M | 1969 |
| Mr. Mark A. Ragosa C.F.A. | Senior Vice President & Chief Financial Officer | 800,778 | 1974 |
| Mr. Ross Michael Moat | Executive Vice President & Chief Commercial Officer | 809,776 | 1980 |
| Mr. Eben Tessari | Executive Vice President & Chief Operating Officer | 818,644 | 1982 |
| Dr. John F. Paolini FACC, M.D., Ph.D. | Executive Vice President & Chief Medical Officer | 893,755 | 1965 |
| Jonathan Kirshenbaum | Investor Relations Officer | 0 | N/A |
| Mr. Chad Morin | Senior Vice President & Chief Compliance Officer | 0 | N/A |
| Ms. Mei Jang | Senior Vice President of Technical Operations | 0 | N/A |
| Mr. Michael R. Megna CPA | Chief Accounting Officer & Group Vice President of Finance | 0 | 1971 |
| Ms. Madelyn Demsky Zeylikman | SVice President, General Counsel & Secretary | 0 | 1974 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.